Latest Headlines

  1. BD, Babson Diagnostics Announce Strategic Partnership Agreement To Enable Small-Volume Blood Collection For Diagnostic Testing In Retail Settings 2/12/2020

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company and Babson Diagnostics, a transformative diagnostic blood testing company, today announced a long-term strategic partnership agreement to bring laboratory-quality, small-volume blood collection to retail pharmacies

  2. Biodesix Announces Initiation Of Clinical Phase Biomarker Development Program With Merck KGaA, Darmstadt, Germany And Pfizer Inc. 2/11/2020

    Biodesix, Inc. announced initiation of the next phase of their biomarker development program with Merck KGaA, Darmstadt, Germany and Pfizer Inc., New York, NY

  3. U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation For Its EsoGuard Esophageal DNA Test 2/11/2020

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company’s majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its EsoGuard™ Esophageal DNA Test on esophageal samples collected using its EsoCheck™ Cell Collection Device in a prevalent well-defined group of patients at elevated risk for esophageal dysplasia due to chronic gastroesophageal reflux disease (GERD)

  4. Predictive Technology Group Announces Beta Test Results For Its ARTguide™ Test 2/11/2020

    Predictive Technology Group (OTC PINK: PRED) (“Predictive” or “The Company”), a leader in helping identify barriers that impact women’s health and build healthier families through its innovations to deliver personalized medicine, today announced that its wholly owned subsidiary, Predictive Laboratories, received interim beta test results from its ARTguide™ test evaluating over 1,000 patients for risk of endometriosis at beta clinical sites

  5. P4 Diagnostix® Announces Acquisition Of Strand Diagnostics And Know Error® 2/11/2020
  6. Expert Fertility Doctor Promotes Increasing Measures To Avoid IVF Mix-Ups 2/10/2020

    In March of last year, a New York City woman gave birth to twins conceived in vitro after years of infertility challenges. After the birth, the couple were stunned to discover that the IVF clinic had implanted the wrong embryos: the twins were biologically related neither to the couple nor to each other

  7. Biocept Enters Into Laboratory Services Agreement With California-Based Independent Physician Association 2/10/2020

    Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it has entered into an agreement with a California-based independent physician association (IPA) to provide its liquid biopsy testing services to physicians and patients in their network

  8. Development Of Novodiag Assay For Safe And Easy Molecular Testing Of Novel Coronavirus And Influenza Viruses 2/10/2020

    Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has initiated development of a Novodiag molecular diagnostic test for the rapid and simultaneous detection of the novel coronavirus (strain 2019-nCoV) and influenza viruses

  9. Zoetis Acquires Ethos Diagnostic Science, A Veterinary Reference Lab Business, To Further Expand Its Comprehensive Diagnostics Capabilities 2/7/2020

    Zoetis Inc. today announced the acquisition of Ethos Diagnostic Science, a veterinary reference lab business dedicated to serving leading specialty animal hospitals, the greater veterinary community and researchers with accurate, reliable results

  10. Blood Test Accurately Identifies HPV-Related Head And Neck Cancer Recurrence; Prospective Clinical Study Published In Journal Of Clinical Oncology 2/5/2020

    A novel blood test can detect recurrent Human Papilloma Virus (HPV)-related head and neck (oropharyngeal) cancers, according to a study published online in the Journal of Clinical Oncology by researchers at the University of North Carolina School of Medicine